Get started
Author

Cagatay Arslan

Observed names: C. Arslan, Ç. Arslan, Çağatay Arslan
ORCID: 0000-0002-3783-7432
Observed ORCID: 0000-0002-3783-7432
OpenAlex ID: A5090181073
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
2023 · Fred Saad, Noel W Clarke, et al. · The Lancet Oncology · 350
PDF
Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).
2023 · Noel W. Clarke, Andrew J. Armstrong, et al. · Journal of Clinical Oncology · 55
1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2022 · F. Saad, A.J. Armstrong, et al. · Annals of Oncology · 13
PDF
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study
2025 · Shun Lu, Oleksandr Vynnychenko, et al. · The Lancet Respiratory Medicine · 7
Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).
2025 · Gunhild Von Amsberg, Urban Emmenegger, et al. · Journal of Clinical Oncology · 7
PDF
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer
2025 · Fred Saad, Andrew J. Armstrong, et al. · European Urology Oncology · 4
PDF
Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS)
2025 · Hatice Bolek, Satı Coskun Yazgan, et al. · European Journal of Cancer · 4
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
2023 · Ahmet Bilici, Omer Fatih Olmez, et al. · Acta Oncologica · 4
PDF
Abstract PO3-04-12: SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i
2024 · Glen Clack, Sercan Aksoy, et al. · Cancer Research · 3
Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).
2025 · Hanny Al-Samkari, Cesar Munoz, et al. · Journal of Clinical Oncology · 2
Impact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC).
2024 · Thomas Yau, Stephen Lam Chan, et al. · Journal of Clinical Oncology · 2
Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
2022 · Ahmet Bilici, Omer Fatih Olmez, et al. · Journal of Clinical Oncology · 2
Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry
2026 · Dilek Tatlıdede, Çağatay Arslan, et al. · Anadolu Kliniği Tıp Bilimleri Dergisi · 1
PDF
Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
2026 · Hatice Bolek, Elif Sertesen Camoz, et al. · Scientific Reports · 1
PDF
Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer
2024 · Deniz Tural, Cagatay Arslan, et al. · Clinical Genitourinary Cancer · 1
PDF
Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors
2022 · Hanny Al-Samkari, Caglayan Geredeli, et al. · Blood · 1
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program
2025 · Deniz Tural, Oğuzcan Özkan, et al. · Future Oncology
PDF
Enhancing outcomes in mCRPC: The impact of androgen receptor inhibitor sequencing before ¹⁷⁷Lu-PSMA-617 therapy.
2025 · Coskun Yazgan, Kamil Kayaş, et al. · Journal of Clinical Oncology
PDF
P075: The Benefits of comprehensive NGS Panels using Liquid Biopsy in Breast Cancer
2025 · S. Karageorgopoulou, A. Koumarianou, et al. · The Breast
145P Efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Impact of hepatitis B virus (HBV) infection
2024 · T. Yau, S.L. Chan, et al. · Annals of Oncology
PDF
Perceptions and expectations: A study on prognostic perception and quality of life in patients with metastatic renal and bladder cancer.
2024 · Hatice Bolek, Cagatay Arslan, et al. · Journal of Clinical Oncology
Immune checkpoints blockade therapies' efficacy and toxicity in patients with impaired renal function in metastatic bladder cancer.
2024 · Deniz Tural, Cagatay Arslan, et al. · Journal of Clinical Oncology
PDF
Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.
2023 · Deniz Tural, Cagatay Arslan, et al. · Journal of Clinical Oncology
P-90 First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis
2022 · A. Isıkdogan, H. Turk, et al. · Annals of Oncology
PDF
P-219 Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study
2021 · Ç. Arslan, U. Kefeli, et al. · Annals of Oncology
Works count: 25
Citation count: 457
H-index: 5
I10-index: 3
Year
Topic
Type